TY - JOUR
T1 - Gutless adenovirus: Last-generation adenovirus for gene therapy
AU - Alba, R.
AU - Bosch, A.
AU - Chillon, M.
PY - 2005/1/1
Y1 - 2005/1/1
N2 - Last-generation adenovirus vectors, also called helper-dependent or gutless adenovirus, are very attractive for gene therapy because the associated in vivo immune response is highly reduced compared to first- and second-generation adenovirus vectors, while maintaining high transduction efficiency and tropism. Nowadays, gutless adenovirus is administered in different organs, such as the liver, muscle or the central nervous system achieving high-level and long-term transgene expression in rodents and primates. However, as devoid of all viral coding regions, gutless vectors require viral proteins supplied in trans by a helper virus. To remove contamination by a helper virus from the final preparation, different systems based on the excision of the helper-packaging signal have been generated. Among them, Cre-loxP system is mostly used, although contamination levels still are 0.1–1% too high to be used in clinical trials. Recently developed strategies to avoid/reduce helper contamination were reviewed. © 2005 Nature Publishing Group. All rights reserved.
AB - Last-generation adenovirus vectors, also called helper-dependent or gutless adenovirus, are very attractive for gene therapy because the associated in vivo immune response is highly reduced compared to first- and second-generation adenovirus vectors, while maintaining high transduction efficiency and tropism. Nowadays, gutless adenovirus is administered in different organs, such as the liver, muscle or the central nervous system achieving high-level and long-term transgene expression in rodents and primates. However, as devoid of all viral coding regions, gutless vectors require viral proteins supplied in trans by a helper virus. To remove contamination by a helper virus from the final preparation, different systems based on the excision of the helper-packaging signal have been generated. Among them, Cre-loxP system is mostly used, although contamination levels still are 0.1–1% too high to be used in clinical trials. Recently developed strategies to avoid/reduce helper contamination were reviewed. © 2005 Nature Publishing Group. All rights reserved.
KW - Adenovirus
KW - Gutless
KW - Helper-dependent vectors
KW - In vivo gene therapy
U2 - 10.1038/sj.gt.3302612
DO - 10.1038/sj.gt.3302612
M3 - Article
SN - 0969-7128
VL - 12
SP - S18-S27
JO - Gene Therapy
JF - Gene Therapy
ER -